Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYEL Lyell Immunopharma	$9.29 -3.1%	$9.12	$7.65 ▼ $38.40	$141.93M	-0.26	70,110 shs	101,670 shs
MRVI Maravai LifeSciences	$2.27 +1.8%	$2.12	$1.67 ▼ $10.03	$567.89M	0.25	2.32 million shs	1.66 million shs
RLAY Relay Therapeutics	$3.26 -1.5%	$3.10	$1.78 ▼ $10.72	$567.48M	1.59	2.09 million shs	1.85 million shs
TSHA Taysha Gene Therapies	$2.44 +3.0%	$2.39	$1.05 ▼ $3.31	$508.75M	1.04	3.05 million shs	2.16 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYEL Lyell Immunopharma	-3.13%	-3.03%	+11.10%	-21.75%	-77.23%
MRVI Maravai LifeSciences	+1.79%	+12.94%	+2.25%	-3.40%	-66.96%
RLAY Relay Therapeutics	-1.51%	-2.98%	+12.03%	+9.03%	-51.63%
TSHA Taysha Gene Therapies	+2.95%	-5.06%	-11.27%	+29.79%	-1.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LYEL Lyell Immunopharma	3.4712 of 5 stars	2.8	3.0	0.0	3.0	5.0	1.3
MRVI Maravai LifeSciences	3.9291 of 5 stars	3.1	3.0	4.4	1.2	0.8	1.3
RLAY Relay Therapeutics	2.4868 of 5 stars	3.4	2.0	0.0	2.0	2.5	0.6
TSHA Taysha Gene Therapies	3.2965 of 5 stars	4.5	1.0	0.0	3.1	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	61.46% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	192.46% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	441.92% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$7.57	210.30% Upside

Current Analyst Ratings Breakdown

Latest LYEL, RLAY, MRVI, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$10.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LYEL Lyell Immunopharma	$60K	2,293.08	N/A	N/A	$26.21 per share	0.35
MRVI Maravai LifeSciences	$259.18M	2.23	$0.63 per share	3.61	$2.28 per share	1.00
RLAY Relay Therapeutics	$10.01M	55.84	N/A	N/A	$4.65 per share	0.70
TSHA Taysha Gene Therapies	$8.33M	62.88	N/A	N/A	$0.35 per share	6.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	8/6/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest LYEL, RLAY, MRVI, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LYEL Lyell Immunopharma	N/A	7.49	7.49
MRVI Maravai LifeSciences	0.60	5.96	5.17
RLAY Relay Therapeutics	N/A	19.96	19.96
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LYEL Lyell Immunopharma	66.05%
MRVI Maravai LifeSciences	50.25%
RLAY Relay Therapeutics	96.98%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
LYEL Lyell Immunopharma	22.30%
MRVI Maravai LifeSciences	2.11%
RLAY Relay Therapeutics	4.87%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LYEL Lyell Immunopharma	270	14.81 million	11.51 million	Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

LYEL, RLAY, MRVI, and TSHA Headlines

Recent News About These Companies

Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $7.57

June 24 at 2:29 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 4, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, RLAY, MRVI, and TSHA Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

$9.29 -0.30 (-3.13%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$9.15 -0.14 (-1.51%)

As of 06/25/2025 06:20 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Maravai LifeSciences NASDAQ:MRVI

$2.27 +0.04 (+1.79%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$2.30 +0.03 (+1.50%)

As of 07:00 AM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Relay Therapeutics NASDAQ:RLAY

$3.26 -0.05 (-1.51%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$3.26 0.00 (0.00%)

As of 06/25/2025 07:26 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$2.44 +0.07 (+2.95%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$2.42 -0.02 (-0.61%)

As of 07:00 AM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time